Compass Pathways PLC
compasspathways.comWhat Do They Do?
Develops an investigational psilocybin treatment for people with treatment-resistant depression and post-traumatic stress disorder.
10-K for FY2025, filed Mar 24, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 24, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$253.8MView ↗
- ▲ +561% (Loss)
- vs −$38.4M in Q2 FY2025
Treatment framing
The older report presents its psilocybin treatment as paired with psychological support; the latest describes the pivotal depression trials as testing psilocybin monotherapy.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 24, 2026Pivotal trial 1 (COMP005) (n=258): a single dose (25mg) monotherapy compared with placebo. Pivotal trial 2 (COMP006) (n=581): a fixed…View ↗
Who Do They Compete With?
Competes with Janssen, Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research, Beckley Psytech, Usona Institute, and Helus Pharma
10-K for FY2025, filed Mar 24, 2026Currently, only two pharmacotherapies are approved for TRD in the U.S.: Spravato (esketamine), marketed by Janssen, which is an NMDA…View ↗
Loading...
